Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01884168|
Recruitment Status : Recruiting
First Posted : June 21, 2013
Last Update Posted : July 19, 2018
|Condition or disease||Intervention/treatment|
|Malignant Tumor||Biological: Dc-CIK immunotherapy|
- The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.
- Malignant cavity effusion from cancer patients is obtained through puncture and is centrifugalized to get supernatant fluid and enrich cancer cells before and after the therapy.
- The enriched cancer cells which are flash frozen, as well as the supernatant, are stored at -80°C until processing.
- The T-Cell Receptor/B-Cell Receptor gene expression in cavity effusion is detected by micro-array to explore the mechanism that DC-CIK immunotherapy controls the malignant cavity effusion.
- Statistical analysis is performed using unsupervised hierarchical cluster.
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Gene Expression Profiling and Immunological Mechanism Affects the Response of Malignant Cavity Effusion Towards DC-CIK Immunotherapy|
|Study Start Date :||March 2013|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||May 2020|
gene expression profile
T-Cell Receptor/B-Cell Receptor gene expression in cavity effusion is detected by micro-array to explore the mechanism that DC-CIK immunotherapy controls the malignant cavity effusion.
Biological: Dc-CIK immunotherapy
The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.
- Immunotherapy response [ Time Frame: 1 month ]T-Cell Receptor and B-Cell Receptor gene expression profiling and the change of cytokines, lymphocytes subpopulation before and after DC-CIK infusion
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01884168
|Contact: Jun Ren, MD, PhDfirstname.lastname@example.org|
|Capital Medical University Cancer Center/Beijing Shijitan Hospital||Recruiting|
|Beijing, Beijing, China, 100038|
|Contact: Jun Ren, MD, PhD 86-10-63926317 email@example.com|
|Principal Investigator:||Jun Ren, MD, PhD||Capital Medical University Cancer Center /Beijing Shijitan Hospital|